GLI2 and medulloblastoma: Furthermore, we identified overexpression of GLI2 and SMO as a signature of resistance to smoothened inhibition in melanoma, as has been reported recently in human medulloblastoma using both NVP-LDE-225 and Vismodegib, an oral SMO inhibitor that is FDA-approved in advanced basal cell carcinoma.